MYUNGMOON Pharm co.,Ltd (KRX:017180)
1,764.00
-18.00 (-1.01%)
At close: Nov 21, 2025
MYUNGMOON Pharm co.,Ltd Revenue
MYUNGMOON Pharm co.,Ltd had revenue of 49.86B KRW in the quarter ending September 30, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to 193.64B, up 7.49% year-over-year. In the year 2024, MYUNGMOON Pharm co.,Ltd had annual revenue of 186.44B with 9.95% growth.
Revenue (ttm)
193.64B
Revenue Growth
+7.49%
P/S Ratio
0.30
Revenue / Employee
665.44M
Employees
291
Market Cap
57.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 186.44B | 16.88B | 9.95% |
| Dec 31, 2023 | 169.57B | 17.43B | 11.46% |
| Dec 31, 2022 | 152.13B | 14.38B | 10.43% |
| Dec 31, 2021 | 137.76B | 9.91B | 7.75% |
| Dec 31, 2020 | 127.85B | -21.49B | -14.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 148.28B |